Jim Radovic

Jim Radovic is a seasoned professional in the pharmaceutical and biotechnology industry with extensive experience in oncology and biosimilar account management. Currently serving as a Senior Account Manager at Biocon Biologics since October 2020, Radovic promotes key oncology drugs including Fulphila, Ogivri, and Hulio. Prior roles include Sickle Cell Therapeutic Specialist at Global Blood Therapeutics and Oncology Key Account Manager at Advanced Accelerator Applications, where significant sales achievements and market expansions were realized. Jim's career includes senior positions at Amgen, Eisai US, AmerisourceBergen, Purdue Pharma L.P., and Sanofi, marked by successful product launches and account development initiatives. Radovic holds a Master of Education degree in Educational Leadership and Administration from The University of Kansas and a Bachelor of Science in Business Administration from the University of California, Riverside.